DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019
DGAP-Ad-hoc: QIAGEN N.V. / Key word(s): Preliminary Results English Version Ad-hoc Announcement pursuant to Article 17 Market Abuse Regulation QIAGEN announces deviation from preliminary sales result expectations for the third quarter of 2019 Venlo, The Netherlands, October 07, 2019 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announces preliminary sales results for the third quarter of 2019 fall short of expectations. For the third quarter of 2019, QIAGEN currently expects preliminary total net sales growth of about 3% at constant exchange rates (CER) compared to the outlook for about 4-5% CER growth, and mainly due to significantly weaker-than-expected developments in China. Total sales growth was about 6% CER excluding China sales. QIAGEN anticipates adjusted EPS within its outlook for approximately $0.35-0.36 CER. QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands ISIN: NL0012169213 Frankfurt Stock Exchange, regulated market (Prime Standard) Contacts John Gilardi Vice President, Head of Corporate Communications and Investor Relations +49 2103 29 11711 and +1 240 686 2222
07-Oct-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | QIAGEN N.V. |
Hulsterweg 82 | |
5912 PL Venlo | |
Netherlands | |
Phone: | +31 7735566 - 00 |
Fax: | +31 77 35566-58 |
E-mail: | [email protected] |
Internet: | www.qiagen.com |
ISIN: | NL0012169213 |
WKN: | A2DKCH |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, Chicago, NYSE, SIX |
EQS News ID: | 886525 |
End of Announcement | DGAP News Service |
|
886525 07-Oct-2019 CET/CEST
QIAGEN NV Stock
With 12 Buy predictions and not the single Sell prediction the community is currently very high on QIAGEN NV.
With a target price of 47 € there is a slightly positive potential of 16.14% for QIAGEN NV compared to the current price of 40.47 €.